الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 237 |  |  |
| | | from | 237 | | |
Abstract
Breast carcinoma has become a major health problem over the past 50years, affecting as many as one in eight women. It is the most common form of malignancy among women. About 25% of women with breast carcinoma eventually will die from the disease. Approximately two-thirds of all breast carcinomas are estrogen dependent and will regress after estrogen deprivation. The aim of this study is to evaluate the effect of different treatment modalities in postmenopausal women with breast cancer with respect to hormonal status This study was performed on postmenopausal breast carcinoma patients referred to Clinical Oncology and Nuclear Medicine Department, Mansoura University Hospitals in the period from 1996 to 2003 inclusive. Postmenopausal female cases represented 30.5% of female breast carcinoma during this period. The mean age was 58.5 years. In postmenopausal estrogen receptor positive patients there is insignificant difference between tamoxifen, femara and chemohormonal adjuvant treatment as regard OAS and DFS. In metastatic cases response rate to treatment and clinical benefit were higher in patients who received femara than in patients who received tamoxifen or chemohormonal therapy. Also, TTF and OAS were higher in patients who received femara than tamoxifen and chemohormonal treatment. Conclusion ” It is very important and mandatory to do hormone receptor assay for every breast carcinoma patients. ” If ER is negative the patients receive chemotherapy. ” If ER is positive tamoxifen can be given in early stage and femara give the best results as an adjuvant treatment in stage II and III and in metastatic cases. Chemotherapy can be given in aggressive or life threatening metastases. Bisphosphonates should be given in association with femara in patients with bone metastases.